VivoSim Lab, Inc.(VIVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VIVS VivoSim Lab, Inc.

交易中 07-22 14:38:34 EDT

0.4698

+0.0198

+4.40%

最高0.4789	最低0.4317	成交量194.58万
今开0.4330	昨收0.4500	日振幅10.49%
总市值164.15万	流通市值121.26万	总股本349.41万
成交额89.43万	换手率75.38%	流通股本258.12万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VIVS","market":"US","secType":"STK","nameCN":"VivoSim Lab, Inc.","latestPrice":0.4698,"timestamp":1784745501482,"preClose":0.45,"halted":0,"volume":1945827,"delay":0,"changeRate":0.04399999999999996,"floatShares":2581200,"shares":3494071,"eps":-5.35,"marketStatus":"交易中","change":0.0198,"latestTime":"07-22 14:38:34 EDT","open":0.433,"high":0.4789,"low":0.4317,"amount":894279.36194064,"amplitude":0.104889,"askPrice":0.4737,"askSize":200,"bidPrice":0.4602,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-5.35,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784750400000},"marketStatusCode":2,"adr":0,"listingDate":1373515200000,"exchange":"NASDAQ","adjPreClose":0.45,"preHourTrading":{"tag":"盘前","latestPrice":0.4426,"preClose":0.45,"latestTime":"09:28 EDT","volume":207028,"amount":93308.47813963999,"timestamp":1784726905634,"change":-0.0074,"changeRate":-0.016444,"amplitude":0.071111},"postHourTrading":{"tag":"盘后","latestPrice":0.45,"preClose":0.45,"latestTime":"19:59 EDT","volume":1476630,"amount":696452.301843,"timestamp":1784678366017,"change":0,"changeRate":0,"amplitude":0.148667},"volumeRatio":0.061581},"requestUrl":"/m/hq/s/VIVS","defaultTab":"news","newsList":[{"id":"1193635789","title":"VivoSim Lab, Inc. 宣布完成400万美元定向增发 依据纳斯达克规则以市价定价 获单一医疗健康领域机构投资者认购","url":"https://stock-news.laohu8.com/highlight/detail?id=1193635789","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193635789?lang=zh_cn&edition=full","pubTime":"2026-07-16 20:31","pubTimestamp":1784205078,"startTime":"0","endTime":"0","summary":"VivoSim Lab, Inc. 已宣布其定向增发定价，成功募集400万美元资金。此次发行严格依据纳斯达克规则，以市价定价，并成功获得一家专注于医疗健康领域的单一机构投资者全额认购。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VIVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122047503","title":"VivoSim Lab获礼来500万美元里程碑付款 并预期2027财年营收增长超500%","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047503","media":"美股速递","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122047503?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:06","pubTimestamp":1784117197,"startTime":"0","endTime":"0","summary":"VivoSim Lab, Inc.宣布，已收到来自全球制药巨头礼来公司的一笔500万美元里程碑付款。与此同时，公司发布了业绩指引，预计在2027财年将实现超过500%的营收增长。这一里程碑付款的达成，标志着双方在特定合作项目上取得了关键进展。VivoSim并未披露具体的合作细节，但此类付款通常与药物研发过程中达到预设的临床或监管目标相关联。投资者将密切关注VivoSim后续的财务报告和业务进展，以验证这一雄心勃勃的增长目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VIVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614049751","title":"Vivosim Labs, Inc.盘中异动 急速上涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614049751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614049751?lang=zh_cn&edition=full","pubTime":"2026-02-26 04:11","pubTimestamp":1772050297,"startTime":"0","endTime":"0","summary":"北京时间2026年02月26日04时11分，Vivosim Labs, Inc.股票出现异动，股价快速上涨5.41%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.46%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226041137a4c85b45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226041137a4c85b45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VIVS","IBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134671302","title":"VivoSim Lab, Inc. 通过韩国和中国新分销协议扩大Namkind™人源毒理学服务在亚太地区的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1134671302","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134671302?lang=zh_cn&edition=full","pubTime":"2026-01-30 05:08","pubTimestamp":1769720903,"startTime":"0","endTime":"0","summary":"VivoSim Lab, Inc. 近日宣布，公司已签署新的分销协议，旨在将旗下Namkind™人源毒理学服务更广泛地引入韩国和中国市场。此举标志着该公司在拓展亚太地区业务版图方面迈出了关键一步，旨在满足该区域日益增长的对先进、可靠毒理学测试方案的需求。\n通过此项战略合作，VivoSim Lab, Inc. 将借助当地分销伙伴的网络与专业优势，提升其创新服务的覆盖范围与市场渗透力。Namkind™技术平台以其基于人类生物学的独特测试模型而著称，有望为亚太地区的药物研发、化学品安全评估及相关生命科学领域提供更精准、更具预测性的人体反应数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VIVS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vivosim.ai","stockEarnings":[{"period":"1week","weight":-0.4609},{"period":"1month","weight":-0.5909},{"period":"3month","weight":-0.6959},{"period":"6month","weight":-0.775},{"period":"1year","weight":-0.7727},{"period":"ytd","weight":-0.7514}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"VivoSim Labs, Inc.成立于2012年1月，从事开发和商业化可以应用在药物发现和开发，进行生物学研究，作为植入受损或退化组织和器官的治疗的人体组织技术平台。VivoSim计划引进到三维人体组织，通过构建三维创作，复制天然人类生物学的潜力。","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":-0.001588},{"month":2,"riseRate":0.538462,"avgChangeRate":0.0713},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.135222},{"month":4,"riseRate":0.461538,"avgChangeRate":-0.007295},{"month":5,"riseRate":0.461538,"avgChangeRate":0.044355},{"month":6,"riseRate":0.153846,"avgChangeRate":-0.092831},{"month":7,"riseRate":0.307692,"avgChangeRate":-0.032764},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.076461},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.037473},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.055078},{"month":11,"riseRate":0.461538,"avgChangeRate":0.059307},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.024045}],"exchange":"NASDAQ","name":"VivoSim Lab, Inc.","nameEN":"VivoSim Lab, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VivoSim Lab, Inc.(VIVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供VivoSim Lab, Inc.(VIVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"VivoSim Lab, Inc.,VIVS,VivoSim Lab, Inc.股票,VivoSim Lab, Inc.股票老虎,VivoSim Lab, Inc.股票老虎国际,VivoSim Lab, Inc.行情,VivoSim Lab, Inc.股票行情,VivoSim Lab, Inc.股价,VivoSim Lab, Inc.股市,VivoSim Lab, Inc.股票价格,VivoSim Lab, Inc.股票交易,VivoSim Lab, Inc.股票购买,VivoSim Lab, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VivoSim Lab, Inc.(VIVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供VivoSim Lab, Inc.(VIVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}